. 2024 May 1;20(5):753–763. doi: 10.5664/jcsm.10998

Table 3.

Sleep diary outcomes.

Measure	Treatment	After Placebo Run-In	After 1 Week of Dosing	After 2 Weeks of Dosing	F	P
Sleep quality	CBD	2.8 (1)	3.4 (1)	3 (1)	8.1_{(2, 582.5)}	<.001*
Sleep quality	PLA	2.9 (1.1)	2.9 (1)	3.1 (0.9)	8.1_{(2, 582.5)}	<.001*
No. of awakenings	CBD	2.1 (1.9)	1.5 (1.6)	1.5 (1.7)	0.4_{(2, 569.1)}	.69
No. of awakenings	PLA	1.7 (1.3)	1.4 (1.7)	1.3 (1.3)	0.4_{(2, 569.1)}	.69
WASO (decimal hours)	CBD	0.6 (0.5)	0.5 (0.6)	0.6 (0.7)	1.3_{(2, 544.1)}	.27
WASO (decimal hours)	PLA	0.6 (0.7)	0.4 (0.7)	0.4 (0.6)	1.3_{(2, 544.1)}	.27
SE (%)	CBD	86.8 (3.1)	86.4 (4.2)	87 (2.7)	1.5_{(2, 567.1)}	.22
SE (%)	PLA	87 (3.8)	85.9 (6)	85.7 (6.3)	1.5_{(2, 567.1)}	.22
SOL (decimal hours)	CBD	0.82 (0.9)	0.6 (0.7)	0.6 (0.7)	0.6_{(2, 576)}	.63
SOL (decimal hours)	PLA	0.9 (0.7)	0.6 (0.8)	0.5 (0.4)	0.6_{(2, 576)}	.63
TST (decimal hours)	CBD	7.94 (1.5)	8 (1.6)	8 (1.5)	1.8_{(2, 566.3)}	.17
TST (decimal hours)	PLA	8 (1.5)	7.8 (1.8)	7.6 (1.8)	1.8_{(2, 566.3)}	.17

Weekly sleep diary–derived raw means, standard deviation, and interaction terms are shown. *Statistically significant effect (P < .05). “No. of awakenings” indicates number of awakenings after sleep onset. CBD = cannabidiol treatment group, PLA = placebo treatment group, SE = sleep efficiency, SOL = sleep-onset latency, TST = total sleep time, WASO = wake after sleep onset.